Products
Pre-made Dalutrafusp Alfa benchmark antibody (Bispecific, anti-NT5E/CD73;TGFB1;TGFB3 therapeutic antibody, Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-793
Pre-made Dalutrafusp Alfa benchmark antibody (Bispecific, anti-NT5E/CD73;TGFB1;TGFB3 therapeutic antibody, Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dalutrafusp alfa is a bispecific antibody-fusion protein that was designed as a checkpoint modulator for immuno-oncology. It was invented by Agenus (as AGEN-1423), and has been licensed to Gilead for clinical development (as GS-1423). The antibody portion of dalutrafusp targets the adenosine degrading enzyme ecto-5'-nucleotidase (NT5E/CD73; produces an immunosuppressive effect in the tumour micoenvironment), and this is fused via a peptidyl linker to the extracellular domain of transforming growth factor beta receptor 2 (TGFBR2) which acts as a molecular trap for both TGFβ1 and TGFβ3. NT5E and TGFβ are two significant resistance pathways that allow tumours to escape immune surveillance.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-793-1mg | 1mg | Inquiry | ||
| GMP-Bios-INN-793-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-793-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-793-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Dalutrafusp Alfa P Alfaiosimilar, Bispecific, Anti-NT5E/CD73;TGFB1;TGFB3 Antibody: Anti-eN/NTE/eNT/CALJA;CED/DPD1/IBDIMDE/LAP/TGF-beta1/TGFbeta;ARVD/ARVD1/LDS5/RNHF therapeutic antibody |
| INN Name | Dalutrafusp Alfa |
| Target | NT5E/CD73;TGFB1;TGFB3 |
| Format | Bispecific |
| Derivation | |
| Species Reactivity | |
| CH1 Isotype | |
| VD LC | |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech |
